Sana Biotechnology, Inc. (SANA) - What Are Analysts Thinking About This Stock?

Key Points

• Analysts are moderately bullish: Ten analysts give Sana Biotechnology an average “Moderate Buy” rating, with seven buys, one strong buy, one hold and one sell. The average 12-month price target is $9.33.
• Sana shares opened at $2.79, near their 52-week low of $2.61 and below both the 50-day and 200-day moving averages. The company recently reported a quarterly loss of $0.13 per share, beating the $0.15 loss expected by analysts.
• Institutional ownership is high at 88.23%: BlackRock, Canada Pension Plan Investment Board, Bank of America, Alphabet and Deutsche Bank all initiated or acquired positions during the second quarter.

Shares of Sana Biotechnology, Inc. (NASDAQ:SANA - Get Free Report) have received an average rating of "Moderate Buy" from the ten analysts that are presently covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, seven have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price target among brokers that have covered the stock in the last year is $9.33.

A number of brokerages recently weighed in on SANA. Wall Street Zen lowered shares of Sana Biotechnology from a "hold" rating to a "sell" rating in a research report on Monday, July 20th. Bank of America decreased their target price on Sana Biotechnology from $7.00 to $6.00 and set a "buy" rating on the stock in a report on Friday, August 14th. Weiss Ratings upgraded Sana Biotechnology from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Thursday, July 23rd. Finally, TD Cowen raised Sana Biotechnology to a "strong-buy" rating in a report on Monday, August 24th.

Sana Biotechnology Price Performance

Shares of NASDAQ SANA opened at $2.79 on Friday. The business has a 50-day moving average of $3.40 and a 200-day moving average of $3.31. The stock has a market capitalization of $835.21 million, a price-to-earnings ratio of -3.67 and a beta of 2.18. Sana Biotechnology has a fifty-two week low of $2.61 and a fifty-two week high of $6.55.

Sana Biotechnology (NASDAQ:SANA - Get Free Report) last released its earnings results on Monday, August 10th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.15) by $0.02. On average, sell-side analysts expect that Sana Biotechnology will post -0.72 EPS for the current year.

Hedge Funds Weigh In On Sana Biotechnology

A number of large investors have recently made changes to their positions in SANA. BlackRock Inc. acquired a new stake in Sana Biotechnology during the 2nd quarter worth approximately $58,196,000. Canada Pension Plan Investment Board acquired a new position in Sana Biotechnology in the 2nd quarter valued at $35,662,000. Bank of America Corp DE bought a new position in Sana Biotechnology during the 2nd quarter worth $20,062,000. Alphabet Inc. bought a new position in Sana Biotechnology during the 2nd quarter worth $9,816,000. Finally, Deutsche Bank AG acquired a new stake in shares of Sana Biotechnology during the second quarter worth $2,251,000. Institutional investors own 88.23% of the company's stock.

About Sana Biotechnology

Sana Biotechnology, Inc is a biotechnology company focused on developing engineered cell and gene therapies intended to treat diseases with significant unmet medical needs. The company's approach is designed to enable the delivery of functional cells or genetic material to patients while addressing challenges such as immune rejection, manufacturing complexity and the need for repeated treatment.

Sana's research programs include both ex vivo therapies, in which cells are modified outside the body before being administered to a patient, and in vivo therapies, which are designed to modify or deliver therapeutic material directly within the body.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.